Cluster Headache Market Research, 2031
The global cluster headache market size valued at $356.00 million in 2021, and is projected to reach $522.98 million by 2031, growing at a CAGR of 3.9% from 2022 to 2031. Cluster headaches are the most common of the primary headache types known as trigeminal autonomic cephalgia. Like other trigeminal autonomic cephalgia's, these headaches can occur every other day to eight times a day. They usually occur at approximately the same time of day, most often at night. Most patients are episodic, with daily attacks for weeks to months, followed by remission for months to years. Cluster headache is a short-lasting unilateral headache with at least one autonomic symptom ipsilateral to the headache, such as lacrimation, nasal congestion, conjunctival injection, or aural fullness. The cluster headache is divided into two types depending upon the period of cluster headache: episodic and chronic. Episodic cluster headache typically lasts for several weeks and occurrences are separated by a remission period of at least 2 weeks. Chronic cluster headache attacks continue for longer than 1 year without remission, or remission is less than 2 weeks.
Market Dynamics
Growth & innovations in the pharmaceutical industry for the manufacturing of cluster headache drugs owing to massive pool of health-conscious consumers, creates an opportunity for the cluster headache market. Rise in launch of various monoclonal antibodies for cluster headache, increase in number of clinical trials of new drugs by various key players across the globe are set to affect the market growth positively. In addition, various drugs are in clinical stages of approval for cluster headache which is projected to fuel the growth of the market. For instance, article published in U.S. National Library of Medicine – Clinical Trials 2022, stated that, Psilocybin is in clinical phase 2 trial which can be used as preventative therapy for cluster headache. Thus, rise in number pipeline medications for cluster headache is anticipated to drive the growth of the market.
In addition, prevalence of cluster headache is increasing in pediatric population, thus driving the growth of the market. For instance, article published in Journal of Head and Face Pain 2021, reported that, 27.5% of pediatric population were diagnosed with cluster headaches. Thus, rise in prevalence of cluster headache in pediatric population is expected to drive the growth of market. The growth of the cluster headache market is expected to be driven by emerging markets, due to availability of improved healthcare infrastructure, increase in unmet healthcare needs, rise in prevalence of cluster cases in adults, and surge in demand for steroidal drugs for management of cluster headache. Furthermore, the healthcare industry in emerging economies is developing at a significant rate, owing to rise in demand for enhanced healthcare services, significant investments by government to improve healthcare infrastructure, and development of the medical tourism industry in emerging countries.
Various organizations along with government are counselling people regarding the headache disorders. E-commerce (electronic commerce) has become a vital tool for small and large businesses globally, due to rise in preference of consumers for online shopping over traditional purchasing methods. Various animations through health apps to educate people regarding headache disorders and usage of medications have contributed toward the growth of cluster headache market. The demand for effective calcium channel blockers and steroids such as prednisone is not only limited to developed countries but is also being witnessed in the developing countries, such as China, Brazil, and India, which fuel the growth of the market. Moreover, increase in promotional activities by manufacturers and growth in awareness for proper treatment medications for cluster headache among the general population is expected to fuel their adoption in the near future.
However, side effects of the drug used in cluster headache restrains the growth of the cluster headache market. In addition, absence of favorable reimbursement policies is expected to constrain the growth of the market. In contrast, rise in demand for novel therapies such as biologics, increase in awareness about treatment options and increase in R&D to develop safe and efficacious drugs for cluster headache treatment offer lucrative opportunities to key players of the cluster headache market.
The outbreak of COVID-19 has disrupted workflows in the health care sector around the world. The COIVID-19 pandemic positively impacted to growth of cluster headache market, owing rise in number of patients suffering from cluster headaches. In addition, many COVID-19 vaccines reported side effects of headache disorders such as cluster headache, thus driving the growth of market. For instance, according to article published in National Library of Medicine 2022, stated that, 628 cases of cluster headache with the COMIRNATY vaccine in 2021. Further, COVID-19 vaccinations triggered new cluster episodes in patients with cluster headache, possibly by activating a pro-inflammatory state of the trigeminocervical complex. For instance, according to article published in according to article published in National Library of Medicine 2022, stated that, many patients in Netherlands reported cluster headache episodes with frequent attacks after vaccination in 2021, thus expected to drive growth of market.
Segmental Overview
The cluster headache market is segmented into type, drug class, distribution channel and region. By type, the market is categorized into episodic and chronic. By drug class, the market is categorized into ergot derivatives, calcium channel blockers, triptans, and others. By distribution channel, the market is categorized into hospital pharmacies, online providers and drug stores and retail pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
By Type
The market is categorized into episodic and chronic. The episodic segment accounted for the largest cluster headache market size in 2021, and is expected to remain dominant during the forecast period, owing to rise in number of people suffering from episodic attack and rise in regulatory approval of drugs indicated for episodic cluster headache.
By Drug Class
The market is categorized into ergot derivatives, corticosteroids, calcium channel blockers, triptans, and others. The triptans segment occupied largest cluster headache market size in 2021 in 2021 and is expected to remain dominant during forecast period owing to first line treatment for cluster headache. The others segment is projected to register highest CAGR during forecast period owing to rise in regulatory approvals of novel drugs and usage in treatment of cluster headache.
By Distribution Channel
The market is categorized into hospital pharmacies, drug stores and retail pharmacies and online providers. The drug stores and retail pharmacies segment occupied largest share in 2021 and is expected to remain dominant during forecast period owing to increase in preference of the people toward retail pharmacies, as retail pharmacies guide regarding medications and usage during treatment period.‐¯ The online providers segment is projected to register highest CAGR during forecast period owing to rise in popularity of online pharmacy and number of users preferring online pharmacies.
By Region
The cluster headache market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for a majority of the global cluster headache market share in 2021, and is anticipated to remain dominant during the forecast period. This is attributed to owing rise in prevalence of cluster headache cases, prevalence of advanced healthcare infrastructure and increase in number of key players offering novel therapeutics, thus expected to drive the growth of cluster headache market. Upsurge in healthcare expenditure in the emerging economies is anticipated to offer lucrative opportunities for the market expansion. However, Asia-Pacific is anticipated to witness notable growth, owing to increasing number of headache disorders, increase in awareness campaign and rise in investments for development of effective drugs for treating cluster headache, is expected to drive the growth of cluster headache market forecast.
Presence of several major players, such as Eli Lilly and Company, AstraZeneca, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd and advancement in manufacturing technology for development of effective medications for headache disorders in the region is expected to drive the growth of cluster headache market. In addition, various private organizations organize educating camps for awareness of cluster headache and treatment options available across the globe is expected to drive growth of this market. Furthermore, presence of well-established healthcare infrastructure, and rise in adoption rate of new medications for treating cluster headache are expected to drive the cluster headache market growth. Furthermore, various product approval and contract agreement as key strategy adopted by the key players in this region further boost the growth of the market.
Asia-Pacific expected to grow at the highest rate during the forecast period. The market growth in this region is attributable to presence of key players in the region. Moreover, rise in adoption of various new medications such as monoclonal antibodies are expected to drive the growth of the market. In India rise in prevalence of headache disorders is observed owing to lifestyle habits such as consumption of alcohol and cigarette smokers, thus driving the growth of market. For instance, according to report of ‘Foundation for Smoke free India 2022’, stated that, 10.7% rise in number of smokers was noted accounting for 267 million tobacco smokers in 2021, thus increasing chances of cluster headache prevalence and driving the cluster headache market opportunity.
Further, many countries such as Australia, awareness programs are been organized every year to educate people about cluster headache and available treatment options. Thus, such awareness campaigns are expected to propel market expansion. Asia-Pacific offers profitable opportunities for key players operating in the cluster headache market, thereby registering the fastest growth rate during the forecast period, owing to the growing infrastructure of industries, rising in spending for headache disorders, as well as well-established presence of domestic companies in the region. In addition, rise in contract manufacturing organizations within the region provides great opportunity for new entrants in this region.
Competitive Analysis
Competitive analysis and profiles of the major players in the cluster headache industry, such as Arrotex Australia Group, AstraZeneca, Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., are provided in this report. Major players have adopted product launch, product approval and contract agreement as key developmental strategies to improve the product portfolio of the cluster headache market.
Some Examples Of Product Approval In The Market
In June 2019, U.S. Food and Drug Administration approved Eli Lilly’s - Emgality (galcanezumab-Gnlm) solution for injection for the treatment of episodic cluster headache in adults.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the cluster headache market analysis from 2021 to 2031 to identify the prevailing cluster headache market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the cluster headache market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global cluster headache market trends, key players, market segments, application areas, and market growth strategies.
Cluster Headache Market Report Highlights
| Aspects | Details |
 Market Size By 2031 | USD 523 million |
 Growth Rate | CAGR of 3.9% |
 Forecast period | 2021 - 2031 |
 Report Pages | 233 |
 By Drug class |
|
 By Distribution channel |
|
 By Type |
|
 By Region |
|
 Key Market Players | Grunenthal, Teva Pharmaceutical Industries Ltd., FRESENIUS SE & Co. KGaA (Fresenius Kabi), Novartis AG, Pfizer Inc., Arrotex Australia Group, Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Eli Lilly and Company |
Analyst Review
This section provides various opinions of top-level CXOs in the global cluster headache market. According to the insights of CXOs, increase in demand for advanced therapeutics and rise in investments for R&D activities related to cluster headache, globally is expected to offer profitable opportunities for the expansion of the market. In addition, favorable government initiatives and higher spending for cluster headache, has surged the interest of several companies to develop novel medications.
CXOs further added that rise in expenditure on the development of healthcare infrastructure and increase in personal disposable income are expected to boost the growth of the cluster headache market. In addition, increase in burden of headache disorders across the globe surges the demand for novel medications, thus driving the growth of the market.
Furthermore, North America accounted for a majority of the global cluster headache market share in 2021, and is anticipated to remain dominant during the forecast period. This is attributed to rise in prevalence of cluster headache cases, prevalence of advanced healthcare infrastructure and increase in number of key players offering novel therapeutics, thus expected to drive the growth of the cluster headache market. Upsurge in healthcare expenditure in the emerging economies is anticipated to offer lucrative opportunities for the market expansion. However, Asia-Pacific is anticipated to witness notable growth, owing to increase in number of headache disorders, rise in awareness campaign, and surge in investments for development of effective drugs for treating cluster headache. This, is expected to drive the growth of the market during the forecast period.
Rise in investments for development of effective medications for cluster headache is the upcoming trend of the market.
Triptans is the leading drug class of cluster headache market.
North America is the largest regional market for cluster headache market.
The cluster headache market valued for $356.00 million in 2021 and is estimated to reach $522.98 million by 2031, exhibiting a CAGR of 3.9% from 2022 to 2031.
Major Key players that operate in the global cluster headache market are Arrotex Australia Group, AstraZeneca, Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd
2021 is the base year of cluster headache market.
2022 to 2031 is the forecast period of cluster headache market.
Loading Table Of Content...
